This session features various discussion groups that are led by a moderator/s who ensures focused conversations around the key issues listed. Attendees choose to join a specific group and the small, informal setting facilitates sharing of ideas and active networking. It will be followed by a refreshment break in the exhibit hall.
11월 28일(수) | 14:50-16:00
Preclinical Models for Cancer Immunotherapy and Combinations
Preclinical Modeling and Combination Therapy Development: Models and Strategies
Sara Colombetti, PhD, Head of Oncology Discovery Pharmacology, Roche Innovation Center Zürich
Michael Rugaard Jensen, PhD, Director, Head of ONC Discovery Pharmacology Basel, Novartis Institutes for BioMedical Research
- Advantages and limitations of preclinical mouse models for immunotherapy evaluation
- How can 3D models help drug discovery in cancer immunotherapy?
- What other animal species, besides the mouse, could be evaluated for in vivo testing of cancer immunotherapies?
- Combination therapy: preclinical considerations
Next Generation 3D Models and Co-Clinical Trials
Christian Schmees, PhD, Head of Tumor Biology, Molecular Biology Department, NMI Natural and Medical Sciences Institute at the University of Tübingen
Optimizing Leads and Predicting Drug Toxicity
Drug Bioactivation: The Good, The
Bad and The Ugly
Axel Pähler, E.R.T., DMPK/PD Leader, Pharmaceutical Sciences (PS), Roche Pharmaceutical Research and Early Development, Roche Innovation Center
- Bioactivation as a risk factor for drug induced toxicities such as DILI
- Case studies of reactive metabolite formation linked to safety failures and key learnings
- Bioactivation reactions that determine the pharmacological mode of action
- Key learnings from old drugs and novel strategies to design selective new inhibitors for safe use
Improving In vitro to In vivo Predictions
Christopher Goldring, PhD, Senior Lecturer, Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool
- Safety testing roadmap being developed by IMI MIP-DILI and TransQST consortia
- Integration of established and emerging test systems - 2D to multi-cell 3D systems
- Use of stem cells in safety assessments
Target Identification & Validation Strategies
CRISPR/Cas9 for Drug Discovery Applications
John Doench, PhD, Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT
Michael Bassik, PhD, Assistant Professor, Department of Genetics, Stanford University
- Impact of CRISPR/Cas9 for drug discovery in pharma and academia
- Applications for functional screens, creating cell lines and disease models
- Design and optimization of low- and high-throughput screens using CRISPR approaches
- Application of CRISPR-knockout, -activation and -inhibition
- Impact of new CRISPR technologies and reagents
Use of Chemical Biology and Chemical Probes in Drug Discovery
Paul Brennan, Ph.D., Associate Professor, Medicinal Chemistry, University of Oxford and Principal Investigator, Target Discovery Institute, Structural Genomics Consortium
- Main applications of Chemical Biology in Drug Discovery projects
- When should Chemical Biology be used in Discovery programs?
- Labelled and label-free proteomic techniques for target identification
NASH and Fibrosis: Translational Research and Strategies
Animal Models for Fibrosis
Bryan C. Fuchs, PhD, Assistant Professor of Surgery, Harvard Medical School
- Who has used what?
- Pros and cons of different models
- What looks promising
NASH Drug Development Challenges
Dean W. Hum, PhD, CSO, Genfit
- Role of biomarkers
- European v. FDA guidance
- Defining target population
11월 29일(목) | 15:05-16:05
3D Cellular Models
Microphysiological Systems for Drug Screening
Hansjoerg Keller, PhD, Sr. Investigator I, Musculoskeletal, Novartis Institutes for BioMedical Research
- Key advantages over classical 2D cell culture models
- Reliability and translatability of human systems
- Applicability, throughput and cost effectiveness
Induced Pluripotent Stem Cells
Human Pluripotent Stem Cells and Their Use as A Massive Platform for Organoid Generation
Nuria Montserrat, PhD, Group Leader, Pluripotency for organ regeneration, Institute for Bioengineering of Catalonia (IBEC)
- How to benefit from bioengineering approaches in order to enhance organoid maturation/vascularization
- Immediate applications from 3D bioprinting using organoids
- Ethic issues related to the use of human pluripotent stem cells
Translational Biomarkers in Immuno-Oncology
Immunological Determinants of Response to Systemic Therapy In Cancer
Sofia Braga, MD, PhD, Assistant Professor, Instituto CUF Oncologia, NOVA Medical School
- Neoplastic cell attributes:
- Neo antigen load
- Mutational burden
- Mismatch repair deficient cells / high microsatelite instability
- Immune system atributes:
- Baseline T cell infiltration: cytotoxic "antitumor" T cells, low tolerogenic T cells
- Other ancillary molecules: PDL1, CD8, B2M
- TCR sequencing
- T cell clones
- Intact immunity
Liquid Biopsy in IO research
Evi Lianidou, PhD, Professor of Clinical Chemistry, University of Athens
- Tumor diagnosis, monitoring, and treatment
- Blood tests / biomarkers
- Mutational analysis of tumors and blood
CNS Models and Translational Strategies
Dish, Animal or Patient: How Can We Best Understand Neurodegenerative Disease?
Stuart W. Hughes, PhD, Director and Head of Pharmacology, Biological Sciences, Vertex Pharmaceuticals
- Is failure in neurodegenerative diseases related to a focus on inappropriate models?
- Can neurodegeneration truly be modeled in vitro?
- Should we pursue the biology of causation or progression?
- What does a ‘validate target’ mean when it comes to neurodegenerative diseases?
Should a Robust Translational Path from Animals to Humans be Required to Advance a Compound?
William Z. Potter MD, PhD, Senior Advisor, National Institute of Mental Health, National Institutes of Health (NIH)
- Should a biomarker of drug effect in human brain always be required to advance a novel compound into efficacy studies
- Does there need to be preclinical data with a homologous biomarkers (e.g. fMRI for both animals and humans)?
- If not, what constitutes adequate evidence that some brain effect observed in animals is occurring in humans?
- Given clinical need are there arguments to advance compounds with some biomarker of acute effect?
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.